Non-pegylated liposomal doxorubicin plus capecitabine as first-line treatment in metastatic breast cancer
Journal Title: OncoReview - Year 2016, Vol 6, Issue 4
Abstract
Purpose: To determine the toxicity and efficacy profile of non-pegylated doxorubicin in combination with capecitabine administered according to LipAX regimen.
Authors and Affiliations
Piotr Plecka
Keywords
Related Articles
- EP ID EP186911
- DOI 10.5604/01.3001.0009.5068
- Views 202
- Downloads 0
PTEN – clinical significance in colorectal cancer
Phosphatase and tensin homolog deleted on chromosome ten (PTEN ) is a human suppressor gene. Its protein product is a bispecific phosphatase playing the complex role in the cell cycle regulating processes and apoptosis b...
Exemestan in breast cancer treatment
Hormonotherapy is one of the most important therapeutic options in the breast cancer treatment, either locally advanced or metastatic. Tamoxifen has been standard of care for many years, however new clinical trials resul...
Off-label drug use in breast cancer therapy
Breast cancer is one of the most common malignancies across the world, including Poland. Chemotherapy plays an important part in the treatment of the disease. Most of the available chemotherapy drugs and regimens have un...
The management and outcome of essential thrombocythemia in pregnancy - single-center experience
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an increase in platelet (PLT > 450 000/μl) and a tendency for either thrombosis or hemorrhage. ET is often diagnosed in elderly life...
Advanced or metastatic non-small-cell lung cancer treatment - new Polish goverment regulation
The article presents the non-small-cell lung cancer current treatment recommendations in consideration of Polish government regulation.